Assistant Professor of CNS Radiation Oncology 🧠 ☢️ at @MDAndersonNews
Houston, TX, USA
Joined March 2018
- Tweets183
- Following2.2K
- Followers1.5K
- Likes1.2K
Brian De, MD retweeted
Brian Thomas Jr PPR points this season
Weeks 1-7 combined 25.5
Week 8 so far 8.2
Brian De, MD retweeted
Michael Goitein Award ceremony at #PTCOG64 honored outstanding young researchers across clinics, biology, physics, and early career research.
Congratulations to Martina Palkowitsch, Claire Rodriguez-Lafrasse, Brian De, and Xiaodong Zhang!
#ParticleTherapy #Oncology
Thank you, Dr. Chang, and the PTCOG community for this honor and for recognizing our work on proton dose intensification for glioblastoma with the Michael Goitein Award.
It has been my great pleasure and honor to serve as the Scientific Program Co-Chair and Clinical Leading Chair for PTCOG for the past four years. I am delighted to witness the advancement of cutting-edge radiation therapy technology and the growth of our talented young colleagues. This will be my last time presenting the Dr. Michael Goitein Award to our outstanding clinical young investigator. @BrianDeMD @PTCOG_Official
Brian De, MD retweeted
Still feels unreal! I am so excited to have matched to @MDAndersonNews for #radonc ! What a journey it’s been to get here! I am so thankful for my incredible wife, my loving family, and all my amazing mentors that invested in me to help make this dream possible!
Brian De, MD retweeted
Thrilled to be presenting our randomized ph2 results on local therapy for oligometastatic #pancreascancer at #GI24 on 1/19.
@MDAndersonNews @ChadTangMD @AlexSherryMD @eugenekoay @ACKoongMDPhD @PrajnanDasMD
@drsmags @DrEmmaHolliday @DrShubhamPant
@DanZhaoMD
Brian De, MD retweeted
BREAKING NEWS
The 2023 #NobelPrize in Physiology or Medicine has been awarded to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
Brian De, MD retweeted
Fascinating presentation from #radonc resident @MDAndersonNews @adam_grippin, travel award winner to #WCLC2023, on temporal relationship of PD-L1 induction and #CovidVaccines in lung cancer diagnostic biopsies. Therapeutic implication being explored!
📣 Exciting news! Thrilled to share that I have started at @MDAndersonNews as an Assistant Professor of Radiation Oncology ☢️, specializing in tumors of the brain and spine 🧠
Grateful for this opportunity to make a meaningful impact in patients' lives 🙏
Brian De, MD retweeted
A prospective study by @MartinTomMD and colleagues showed that PET/CT with 18F-fluciclovine, a repurposed widely available radiotracer, has promising ability to distinguish radiation necrosis from tumor progression after #radiosurgery.
Read more: link.springer.com/article/10…
Brian De, MD retweeted
Stellar @baylormed MS3 Marcus Flores presents on how the PRISM score stratifies outcomes for patients treated with SSRS @MDAndersonNews and Mayo. Important implications to individualize treatment for patients! Thanks for excellent mentorship @BrianDeMD!
Brian De, MD retweeted
Excited to share our work on the incidence of PEP changes in phase 3 clinical trials. I'm grateful for the opportunity to work on such an impactful project under the mentorship of @ebludmir and @JAbiJaoude. Thnx to the support of our team @MDAndersonNews jamanetwork.com/journals/jam…
Brian De, MD retweeted
@MarcusAFlorez @JAbiJaoude and team reporting on PEP changes after enrollment begins; policy rec - need COMPLETE protocol published w trials, including history of changes. @RKouzyMD @TaniguchiMD @cd_fuller @roshalp @michael_overman @BrianDeMD @mekupferman
Among registered phase 3 cancer trials, 19% had the primary endpoint (PEP) change after enrollment began. 70% of changes were not reported, and PEP change is associated with positive PEP results. ja.ma/459paSr
Brian De, MD retweeted
Men with cT4 prostate ca have significant morbidity associated w/ local disease burden.
Definitive local therapy with☢️ or🔪 was associated w/ 📈 LRFS, DFS, CRFS, and OS, even in men with M1 disease!
bjui-journals.onlinelibrary.…
Brian De, MD retweeted
There has been a lot of 🔥discussion lately of short course radiation (SCRT) for locally advanced rectal cancer (LARC).
I❤️SCRT bc it is convenient for working patients or those who travel for 🏥care. However, the RAPIDO update gives me pause. Let’s look at the history of SCRT:
Brian De, MD retweeted
Marion U. Schwartz Memorial Research Fellowship: Supported by CCF.
Ethan Ludmir, The University of Texas MD Anderson Cancer Center
Integrating Radiomics and Immunogenomics to Predict Tumor-Related Liver Failure for Patients with Metastatic Intrahepatic Cholangiocarcinoma.
Brian De, MD retweeted
Kids asleep,🧵time: EXTEND is randomized basket trial testing whether MDT improves PFS for oligometastatic cancers. The primary analysis for each histology-specific basket. Thanks to @JAMAOnc for reporting the prostate intermittent hormone basket here: bit.ly/3mgrQfE
Brian De, MD retweeted
Packed house for the Ritsuko and James Cox Lectureship!Thank you @_APollack for your Grand Rounds lecture & for spending the day with our residents.This is a beautiful way to honor a giant in our field who was tirelessly committed to education. We miss him so much. @ACKoongMDPhD – at Texas Medical Center, Houston
Brian De, MD retweeted
Delighted to share our most recent work investigating #aging after #WBRT, published in Neuro-0ncology @NeuroOnc. Free access link: academic.oup.com/neuro-oncol…
Brian De, MD retweeted
We introduce #DeepGlioma, the first AI-based molecular classification system for diffuse gliomas. DeepGlioma was developed by @mlins_lab at @umichneuro with our incredible collaborators. Check out the paper in @NatureMedicine at nature.com/articles/s41591-0….
Brian De, MD retweeted
Had a great dinner tonight celebrating the achievements of these outstanding humans! So proud they are directing some of their interest & talents to projects studying late toxicity & patient reported outcomes for folks w/ anal & rectal cancers! #HollidayNonLab @MDAndersonNews
